



Supplement Figure 2


2A Subgroup analysis based on ctDNA detection timing (DFS/RFS)




2C Subgroup analysis based on ctDNA detection timing (OS)



2B Subgroup analysis based on ctDNA detection timing (EFS)



2D Subgroup analysis based on ctDNA detection timing (PFS)



Supplement Figure 2 - Forest plots of studies demonstrating the association between circulating tumor DNA positivity and survival outcomes in solid cancer patients who received neoadjuvant treatment across different ctDNA detection timing. (A) Disease-free survival/recurrence-free survival in baseline, preoperative, and postoperative settings. (B) Event-free survival in baseline, preoperative, and postoperative settings. (C) Overall survival in baseline, preoperative, and postoperative settings. (D) Progression-free survival in preoperative, and postoperative settings. DFS/RFS, disease-free survival/recurrence-free survival; OS, overall survival; EFS, event-free survival; PFS, progression-free survival; HR, Hazard ratio.